Breaking Update
Israeli Biotech Partners with Norwegian Firm on New Brain Cancer Drug
Israeli biotech company BioLineRx partners with Norwegian firm Hemispherian AS to develop new brain cancer drug GLIX1, targeting cancer cells' DNA repair. FDA
Jerusalem, 29 September, 2025 (TPS-IL) — BioLineRx Ltd., an Israeli biopharmaceutical company, has partnered with Oslo-based Hemispherian AS to develop GLIX1, a new oral drug for glioblastoma and other cancers. GLIX1 targets cancer cells’ DNA repair, causing tumor-specific cell death while leaving healthy cells intact. The FDA has cleared an Investigational New Drug application, with a Phase 1/2a trial expected to start in early 2026.
BioLineRx will manage and fund the project, initially holding a 40% stake, while Hemispherian owns 60%.
